141 related articles for article (PubMed ID: 14652795)
41. Magnetic resonance imaging in multiple sclerosis.
Napoli SQ; Bakshi R
Rev Neurol Dis; 2005; 2(3):109-16. PubMed ID: 16400309
[TBL] [Abstract][Full Text] [Related]
42. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
43. Natalizumab treatment in pediatric multiple sclerosis: a case report.
Borriello G; Prosperini L; Luchetti A; Pozzilli C
Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
[TBL] [Abstract][Full Text] [Related]
44. [CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin].
Caudie C; Bancel J; Dupont M; Matanza D; Poitevin F; Honnorat J
Ann Biol Clin (Paris); 2005; 63(6):631-7. PubMed ID: 16330382
[TBL] [Abstract][Full Text] [Related]
45. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis.
Anderson SA; Shukaliak-Quandt J; Jordan EK; Arbab AS; Martin R; McFarland H; Frank JA
Ann Neurol; 2004 May; 55(5):654-9. PubMed ID: 15122705
[TBL] [Abstract][Full Text] [Related]
46. Beta 2-microglobulin: its significance and clinical usefulness.
Bethea M; Forman DT
Ann Clin Lab Sci; 1990; 20(3):163-8. PubMed ID: 2188562
[TBL] [Abstract][Full Text] [Related]
47. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
48. Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.
Bagnato F; Ohayon JM; Ehrmantraut M; Chiu AW; Riva M; Ikonomidou VN
Expert Rev Neurother; 2006 Apr; 6(4):599-612. PubMed ID: 16623658
[TBL] [Abstract][Full Text] [Related]
49. Early treatment of multiple sclerosis to prevent neurologic damage.
Coyle PK
Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
[TBL] [Abstract][Full Text] [Related]
50. The role of MRS and fMRI in multiple sclerosis.
Tartaglia MC; Arnold DL
Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835
[TBL] [Abstract][Full Text] [Related]
51. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
52. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.
Gottenberg JE; Busson M; Cohen-Solal J; Lavie F; Abbed K; Kimberly RP; Sibilia J; Mariette X
Ann Rheum Dis; 2005 Jul; 64(7):1050-5. PubMed ID: 15640273
[TBL] [Abstract][Full Text] [Related]
53. CSF neopterin as marker of disease activity in multiple sclerosis.
Fredrikson S; Link H; Eneroth P
Acta Neurol Scand; 1987 May; 75(5):352-5. PubMed ID: 3618112
[TBL] [Abstract][Full Text] [Related]
54. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis.
Giovannoni G; Lai M; Kidd D; Thorpe JW; Miller DH; Thompson AJ; Keir G; Feldmann M; Thompson EJ
Brain; 1997 Jan; 120 ( Pt 1)():1-13. PubMed ID: 9055793
[TBL] [Abstract][Full Text] [Related]
55. Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis.
Fominykh V; Brylev L; Gaskin V; Luzin R; Yakovlev A; Komoltsev I; Belousova I; Rosliakova A; Guekht A; Gulyaeva N
Metab Brain Dis; 2019 Oct; 34(5):1473-1485. PubMed ID: 31267347
[TBL] [Abstract][Full Text] [Related]
56. Cerebrospinal fluid beta 2-microglobulin in multiple sclerosis and other neurological diseases.
Merelli E; Previdi P; Sola P; Faglioni P
Acta Neurol (Napoli); 1983 Jun; 5(3):184-9. PubMed ID: 6193683
[No Abstract] [Full Text] [Related]
57. Age-adjusted CSF β2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
Haarmann A; Hähnel L; Schuhmann MK; Buttmann M
J Neuroimmunol; 2018 Oct; 323():19-27. PubMed ID: 30196829
[TBL] [Abstract][Full Text] [Related]
58. Increased urinary neopterin: creatinine ratio as a marker of activation of cell-mediated immunity and oxidative stress in the Iranian patients with multiple sclerosis.
Khorami H; Neyestani T; Kadkhodaee M; Lotfi J
Iran J Allergy Asthma Immunol; 2003 Sep; 2(3):155-8. PubMed ID: 17301373
[TBL] [Abstract][Full Text] [Related]
59. Activated Cellular Immunity in Chronic Hepatitis C.
Diez-Ruiz A; Norkrans G; Wejstal R; Weiland O; Tilz GP; Wachter H; Fuchs D
Hematology; 1996; 1(1):75-8. PubMed ID: 27406302
[TBL] [Abstract][Full Text] [Related]
60. Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase.
Martínez-Brú C; Cortés M; Planella T; Barrio J; Cadafalch J; Domingo P; Fuster M; Sambeat MA; González-Sastre F
Ann Clin Biochem; 1999 Sep; 36 ( Pt 5)():601-8. PubMed ID: 10505209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
